Zanubrutinib plus pola-R-CHP and high-dose methotrexate for secondary CNS lymphoma
Treatments studied
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This trial tests a combination of targeted therapy (zanubrutinib) plus a standard chemo-immunotherapy regimen (pola-R-CHP) and high-dose methotrexate for people whose large B-cell lymphoma has spread to the brain or spinal cord. The goal is to see if this approach can effectively treat lymphoma in both the body and the central nervous system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of large B-cell lymphoma that has spread to your brain or spinal cord (called secondary CNS lymphoma).
- You must have lymphoma in other parts of your body too, not just the central nervous system.
- You cannot have received prior treatment with a specific class of chemotherapy drugs called anthracyclines (like doxorubicin) for lymphoma.
- Your heart, kidneys, liver, and blood counts must be within certain safe ranges for study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding either methotrexate or thiotepa to the standard R-CHOP regimen plus orelabrutinib can better treat diffuse large B-cell lymphoma (DLBCL) that has spread to the central nervous system (brain or spinal cord). The goal is to see if these combinations improve outcomes for patients with this type of lymphoma.
This trial tests zanubrutinib (a targeted lymphoma medicine) together with pemetrexed (chemotherapy) for lymphoma that has come back or did not respond well in or around the brain. It may help shrink measurable lymphoma and improve control of disease after prior treatments.
This trial tests a new drug called zanubrutinib combined with standard chemotherapy for people newly diagnosed with a type of brain lymphoma. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a combination of three drugs — high-dose methotrexate, thiotepa, and zanubrutinib — for people newly diagnosed with primary central nervous system lymphoma (PCNSL). The goal is to see if this combination is safe and effective in shrinking tumors and improving outcomes.
This trial tests a combination of chemotherapy and a targeted drug (zanubrutinib) for people with a type of lymphoma (DLBCL) that has spread to the brain or spinal fluid. The goal is to see if this treatment can better control the disease and improve outcomes.
This Phase 2 trial studies a combination of anti-cancer medicines to treat lymphoma that is only in the brain/spinal fluid (central nervous system, or CNS), especially when it has come back or not responded. If you qualify, you may benefit from improved tumor control and possibly better symptom control.
Hear when a new CNS Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.